Amphipathic peptides can act as an anticoagulant by competing with phospholipid membranes for blood coagulation factors.

[1]  W. Ageno.  Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials , 2009, Expert review of cardiovascular therapy.

[2]  H. Bounameaux.  The novel anticoagulants: entering a new era. , 2009, Swiss medical weekly.

[3]  Christopher R. Emerson,et al.  Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor , 2009, Pharmacotherapy.

[4]  J. Ansell,et al.  Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict , 2008 .

[5]  S. Spinler,et al.  Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases , 2008, Pharmacotherapy.

[6]  Henry T. Peng,et al.  Characterization of an ideal amphipathic peptide as a procoagulant agent. , 2008, The Biochemical journal.

[7]  J. Hirsh,et al.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[8]  P. Shek,et al.  The Use of Ideal Amphipathic Helical Peptides To Reduce Hemorrhage In Vivo. , 2007 .

[9]  E. Frenkel,et al.  Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. , 2005, Hematology/oncology clinics of North America.

[10]  G. E. Gilbert,et al.  Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. , 2003, Blood.

[11]  B. Furie,et al.  The Gla Domain of Human Prothrombin Has a Binding Site for Factor Va* , 2000, The Journal of Biological Chemistry.

[12]  M. Blostein,et al.  Amphipathic helices support function of blood coagulation factor IXa. , 2000, Biochemistry.

[13]  B. Furie,et al.  Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid , 1999 .

[14]  J. Dufourcq,et al.  The amphipathic helix concept: length effects on ideally amphipathic LiKj(i=2j) peptides to acquire optimal hemolytic activity. , 1999, Biochimica et biophysica acta.

[15]  K. Croce,et al.  Interaction between soluble P-selectin and soluble P-selectin glycoprotein ligand 1: equilibrium binding analysis. , 1998, Biochemistry.

[16]  K. Ohashi,et al.  Cell Adhesion to Phosphatidylserine Mediated by a Product of Growth Arrest-specific Gene 6* , 1997, The Journal of Biological Chemistry.

[17]  J. Rand,et al.  Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. , 1997, The New England journal of medicine.

[18]  Margaret Jacobs,et al.  Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX* , 1996, The Journal of Biological Chemistry.

[19]  B. Seaton,et al.  Ca2+-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V , 1995, Nature Structural Biology.

[20]  J. Dufourcq,et al.  The amphipathic α‐helix concept , 1994 .

[21]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[22]  J. Hirsh.  Oral anticoagulant drugs. , 1991, The New England journal of medicine.

[23]  Kenneth G. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .

[24]  J. Bloom.  The interactions of factors X and IX with phospholipid. , 1989, Thrombosis research.

[25]  J. Rosing,et al.  Calcium-independent activation of prothrombin on membranes with positively charged lipids. , 1988, Biochemistry.

[26]  C. Esmon,et al.  The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. , 1987, The Journal of biological chemistry.

[27]  P. Comfurius,et al.  Changes in membrane phospholipid distribution during platelet activation. , 1983, Biochimica et biophysica acta.

[28]  A. Bangham,et al.  A Correlation between Surface Charge and Coagulant Action of Phospholipids , 1961, Nature.

[29]  Y. Seki.  [Unfractionated heparin]. , 2011, Rinsho byori. The Japanese journal of clinical pathology.

[30]  P. D. de Groot,et al.  Tests for lupus anticoagulant revisited. , 2004, Thrombosis research.

[31]  G. Huang,et al.  Structural basis of membrane binding by Gla domains of vitamin K–dependent proteins , 2003, Nature Structural Biology.

[32]  B. Furie,et al.  Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. , 1999, Blood.

[33]  J. Dufourcq,et al.  The amphipathic alpha-helix concept. Application to the de novo design of ideally amphipathic Leu, Lys peptides with hemolytic activity higher than that of melittin. , 1994, FEBS letters.

[34]  K. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes. , 1990, Blood.